Spots Global Cancer Trial Database for yervoy
Every month we try and update this database with for yervoy cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Adoptive Therapy Using Antigen-Specific CD4 T-Cells | NCT02210104 | Melanoma Sarcoma | Ipilimumab Cyclophosphamid... CD4+ T cells | 18 Years - | M.D. Anderson Cancer Center | |
| A Phase 1/2 Safety Study of Intratumorally Dosed INT230-6 | NCT03058289 | Breast Cancer Head and Neck C... Squamous Cell C... Lymphoma Pancreatic Canc... Liver Cancer Colon Cancer Lung Cancer Bile Duct Cance... Chordoma of Sac... Sarcoma | INT230-6 anti-PD-1 antib... anti-CTLA-4 ant... | 18 Years - | Intensity Therapeutics, Inc. | |
| Ipilimumab + Androgen Depravation Therapy in Prostate Cancer | NCT01377389 | Prostate Cancer | Ipilimumab Leuprolide Goserelin Degarelix | 18 Years - | M.D. Anderson Cancer Center | |
| Nivolumab, Ipilimumab, and Bicalutamide in Human Epidermal Growth Factor (HER) 2 Negative Breast Cancer Patients | NCT03650894 | Breast Neoplasm... Breast Cancer Breast Carcinom... Breast Tumor | Nivolumab Ipilimumab Bicalutamide | 18 Years - | Providence Health & Services | |
| Single Arm Trial of Tumor-Treating Fields in Combination With Nivolumab and Ipilimumab in Metastatic Uveal Melanoma | NCT05004025 | Uveal Melanoma | Novocure Optune Opdivo Yervoy | 18 Years - 100 Years | HonorHealth Research Institute | |
| A Phase I/II Trial to Evaluate a Peptide Vaccine Plus Ipilimumab in Patients With Melanoma | NCT02385669 | Melanoma | Ipilimumab 6MHP | 18 Years - | University of Virginia | |
| A Study to Assess BMS-986207 in Combination With Nivolumab and Ipilimumab as First-line Treatment for Participants With Stage IV Non-Small Cell Lung Cancer | NCT05005273 | Non-Small Cell ... | Nivolumab Ipilimumab BMS-986207 Placebo | 18 Years - | Bristol-Myers Squibb | |
| Neoadjuvant Immunotherapy in Brain Metastases | NCT04434560 | Brain Metastase... | Nivolumab Ipilimumab | 18 Years - | Duke University | |
| IPI-Biotherapy for Patients Previously Treated With Cytotoxic Drugs With Metastatic Melanoma | NCT01409187 | Melanoma | Ipilimumab Interferon Interleukin-2 (... | 18 Years - 65 Years | M.D. Anderson Cancer Center | |
| Phase I Study of Intralesional Bacillus Calmette-Guerin (BCG) Followed by Ipilimumab in Advanced Metastatic Melanoma | NCT01838200 | Metastatic Mela... | Bacillus Calmet... Ipilimumab Isoniazid | 18 Years - | Ludwig Institute for Cancer Research | |
| Ipilimumab (Immunotherapy) and MGN1703 (TLR Agonist) in Patients With Advanced Solid Malignancies | NCT02668770 | Advanced Cancer... Melanoma | MGN1703 Ipilimumab | 18 Years - | M.D. Anderson Cancer Center | |
| Concurrent Ipilimumab and Stereotactic Ablative Radiation Therapy (SART) for Oligometastatic But Unresectable Melanoma | NCT01565837 | Melanoma | Ipilimumab Stereotactic Ab... | 18 Years - | Comprehensive Cancer Centers of Nevada | |
| Adoptive Therapy Using Antigen-Specific CD4 T-Cells | NCT02210104 | Melanoma Sarcoma | Ipilimumab Cyclophosphamid... CD4+ T cells | 18 Years - | M.D. Anderson Cancer Center | |
| A Biomarker Study in Advanced Mucosal or Acral Lentiginous Melanoma Receiving Nivolumab in Combination With Ipilimumab | NCT02978443 | Acral Lentigino... Mucosal Melanom... | Nivolumab Ipilimumab | 18 Years - | Georgetown University | |
| Phase II Study of Abraxane Plus Ipilimumab in Patients With Metastatic Melanoma | NCT01827111 | Melanoma | ABI-007 Ipilimumab Phone Call | 12 Years - 70 Years | M.D. Anderson Cancer Center | |
| IPI-Biotherapy for Patients Previously Treated With Cytotoxic Drugs With Metastatic Melanoma | NCT01409187 | Melanoma | Ipilimumab Interferon Interleukin-2 (... | 18 Years - 65 Years | M.D. Anderson Cancer Center | |
| Adoptive Therapy Using Antigen-Specific CD4 T-Cells | NCT02210104 | Melanoma Sarcoma | Ipilimumab Cyclophosphamid... CD4+ T cells | 18 Years - | M.D. Anderson Cancer Center | |
| A Phase 1/2 Safety Study of Intratumorally Dosed INT230-6 | NCT03058289 | Breast Cancer Head and Neck C... Squamous Cell C... Lymphoma Pancreatic Canc... Liver Cancer Colon Cancer Lung Cancer Bile Duct Cance... Chordoma of Sac... Sarcoma | INT230-6 anti-PD-1 antib... anti-CTLA-4 ant... | 18 Years - | Intensity Therapeutics, Inc. | |
| A Biomarker Study in Advanced Mucosal or Acral Lentiginous Melanoma Receiving Nivolumab in Combination With Ipilimumab | NCT02978443 | Acral Lentigino... Mucosal Melanom... | Nivolumab Ipilimumab | 18 Years - | Georgetown University | |
| An Investigational Immuno-Therapy Safety and Efficacy Study of Multiple Administration Regimens for Nivolumab Plus Ipilimumab in Subjects With Renal Cell Carcinoma | NCT03029780 | Renal Cell Carc... | Opdivo Yervoy | 18 Years - | Bristol-Myers Squibb | |
| A Study to Assess BMS-986207 in Combination With Nivolumab and Ipilimumab as First-line Treatment for Participants With Stage IV Non-Small Cell Lung Cancer | NCT05005273 | Non-Small Cell ... | Nivolumab Ipilimumab BMS-986207 Placebo | 18 Years - | Bristol-Myers Squibb | |
| T-Cell Responses to Neoantigens Post Treatment With Ipilimumab in Men With Metastatic Castration-Resistant Prostate Cancer | NCT02113657 | Prostate Cancer | Ipilimumab | 18 Years - | M.D. Anderson Cancer Center | |
| Ipilimumab, Nivolumab, Tocilizumab and Radiation in Pretreated Patients With Advanced Pancreatic Cancer | NCT04258150 | Pancreatic Canc... | Nivolumab Ipilimumab Tocilizumab SBRT | 18 Years - | Herlev Hospital | |
| Ipilimumab and Stereotactic Body Radiation Therapy (SBRT) in Advanced Solid Tumors | NCT02239900 | Liver Cancer Lung Cancer | Ipilimumab Stereotactic Bo... | 18 Years - | M.D. Anderson Cancer Center | |
| Doxycycline, Temozolomide and Ipilimumab in Melanoma | NCT01590082 | Melanoma | Doxycycline Ipilimumab Temozolomide | 18 Years - | M.D. Anderson Cancer Center | |
| Ipilimumab + Androgen Depravation Therapy in Prostate Cancer | NCT01377389 | Prostate Cancer | Ipilimumab Leuprolide Goserelin Degarelix | 18 Years - | M.D. Anderson Cancer Center | |
| Nivolumab in Combination With Ipilimumab in Patients With Metastatic Renal Cell Carcinoma | NCT03297593 | Renal Cell Carc... | nivolumab ipilimumab | 18 Years - | Swiss Group for Clinical Cancer Research | |
| Ipilimumab (Immunotherapy) and MGN1703 (TLR Agonist) in Patients With Advanced Solid Malignancies | NCT02668770 | Advanced Cancer... Melanoma | MGN1703 Ipilimumab | 18 Years - | M.D. Anderson Cancer Center | |
| Yervoy Pregnancy Surveillance Study | NCT02854488 | Melanoma | Yervoy | - | Bristol-Myers Squibb | |
| Yervoy With Sylatron Unresectable Stage 3 or 4 Melanoma | NCT01496807 | Melanoma | Sylatron Yervoy | 16 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| An Investigational Immuno-Therapy Safety and Efficacy Study of Multiple Administration Regimens for Nivolumab Plus Ipilimumab in Subjects With Renal Cell Carcinoma | NCT03029780 | Renal Cell Carc... | Opdivo Yervoy | 18 Years - | Bristol-Myers Squibb | |
| IPI Biochemotherapy for Chemonaive Patients With Metastatic Melanoma | NCT01409174 | Melanoma | Ipilimumab Temozolomide Cisplatin Interferon Alfa... Interleukin-2 | 18 Years - 65 Years | M.D. Anderson Cancer Center | |
| Ipilimumab and Lenalidomide in Advanced Cancer | NCT01750983 | Advanced Cancer... | Ipilimumab Lenalidomide | 18 Years - | M.D. Anderson Cancer Center | |
| Ipilimumab (Immunotherapy) and MGN1703 (TLR Agonist) in Patients With Advanced Solid Malignancies | NCT02668770 | Advanced Cancer... Melanoma | MGN1703 Ipilimumab | 18 Years - | M.D. Anderson Cancer Center | |
| Study of Lenalidomide/Dexamethasone With Nivolumab and Ipilimumab in Patients With Newly Diagnosed Multiple Myeloma | NCT03283046 | Malignant Neopl... Multiple Myelom... | Nivolumab Lenalidomide Dexamethasone Ipilimumab | 18 Years - | M.D. Anderson Cancer Center |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
